A study by Seecheran et al. found that treatment with dapagliflozin significantly reduced platelet reactivity, as evidenced by a 20% reduction in P2Y12 reaction units (PRUs), in patients with type 2 diabetes and stable coronary artery disease. This evidence concerns the gene P2RY12 and type 2 diabetes mellitus.